As published in The Australian, Prof Richard Scolyer AO’s friends and colleagues, Professor Georgina Long AO and Dr Kerry Crotty, share their reflections on Richard’s extraordinary spirit, his exceptional contributions to the fields of melanoma and pathology, and his lasting legacy.
Over the next three months, Prof Georgina Long will work with some of Europe's leading cancer research and treatment centres, advancing collaborative research in melanoma and neoadjuvant immunotherapy.
Read more about how the MIA team continues to play a leading role in advancing the frontiers of melanoma research, presenting new findings at major international oncology conferences - the AACR Annual Meeting in San Diego, the EADO Congress in Prague, and ASCO in Chicago.
Leading Melanoma Institute Australia clinicians and researchers are in Europe to share latest research findings and clinical updates with international colleagues as we continue our efforts to reach zero deaths from melanoma.
Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
Read more about MIA clinicians and researchers in Chicago for ASCO25 - the American Society of Clinical Oncology Annual Meeting - to share latest research and clinical trial results with international colleagues.
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
